Michael J. Fox Foundation Nrf2 Research Study
The Michael J. Fox Foundation is proactively pursuing a solution to slowing down the progression of Parkinson’s disease. Parkinson’s is characterized by a constant loss of substantia nigra (specific cells of the brain region) which is responsible for the production of the chemical messenger dopamine.
MS and Nrf2 Michael J Fox

The Michael J. Fox Foundation is proactively pursuing a solution to slowing down the progression of Parkinson's disease.  Parkinson's is characterized by a constant loss of substantia nigra (specific cells of the brain region) which is responsible for the production of the chemical messenger dopamine.

Current Parkinson's therapy is involves administering drugs that mimic dopamine action. However, one of the downsides of the current approach is that the treatment becomes less effective as the disease progresses. In addition, the side effects of these treatments increase as the disease advances.

The field of free radical biology is not a new one, in fact it had its beginnings about 40 years ago. One of the approaches of free radical biology involves (re)activating the NRF2 pathway in which the body up-regulates the production of antioxidant oxidants and survival genes. At the same time the activated NRF2 down-regulates fibrosis and inflammation.

The Michael J. Fox Foundation pre-clinical model is administered through an oral dose of pioglitazone and trials are underway to test whether the NRF2 activation can prevent dopaminergic nigral cell loss. If so this approach may produce a simple alternative strategy to prevent the progression of the disease in PD patients. Parkinson's falls into a group of over 200 diseases tied to oxidative stress. If this approach is successful there may be associated benefits for the other 200 illnesses and in particular other neurodegenerative disorders.

Sign Up for Our Newsletter



Read More

Oxidative Stress
New Protandim Study – International Formula Impact on Oxidative Stress
There are numerous studies about the USA Protandim formula. This one is about the International formulation.
Augusta Nrf2 Study
Augusta University Discovers How Nrf2 Activator Preserves Sight in Retinal Degeneration Model
“We are very, very pleased that we can now explore the mechanisms,”, mentioned Dr. Sylvia Smith, chair of the Department of Cellular Biology and Anatomy at the Medical College of Georgia at Augusta University and co-director of the James and Jean Culver Vision Discovery Institute at AU.
persistent fibrosis
Reversal of persistent fibrosis in aging by targeting nox4-Nrf2 redox imbalance – Sciencemag.org
This is a promising study because the current treatments of pathological and cystic fibrosis are costly and very time consuming. Persistent fibrosis in lungs of aged mice was caused by the loss of cellular redox balance. The mice in the study with low NRF2 expression had a higher incidence of progressive lung disease. Tissues from human lung samples demonstrated this same Nox4-Nrf2 imbalance.

Next Steps

Get Our Free Newsletter

View Resources

Take Our Quiz

0

PROJECTS COMPLETED

0

ACTIVE CLIENTS

0

CUPS OF COFFEE

0

HAPPY CLIENTS

TESTIMONIALS

What They Say?

SEND US YOUR FEEDBACK

Get a face-to-face appoinment with our qualified specialists

PHONE NUMBER

+ 924 888 0250

EMAIL ADDRESS

hello@spirit.health

OUR LOCATION

Crown Rd. 14b, San Diego, California


© 2021 / Spirit Health / All rights reserved

Malcare WordPress Security